PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for ...

Revenues of €7.0 million, corresponded to the sale of 17 Aeson® artificial hearts for commercial implants (Germany, Italy, Spain, and Poland) and to the sale of 25 Aeson® artificial hearts in the ...

On July 3, 2025, CARMAT had announced the initiation of a call for public tenders (buyers or investors) as part of the receivership opened on July 1, 2025. The deadline for submitting offers was July ...

Carmat, the French company behind the world’s most advanced total artificial heart, Aeson, has been ordered into liquidation by the Versailles Economic Activities Court. Once hailed as a breakthrough ...

The U.S. FDA’s decision to grant breakthrough device designation for Bivacor Inc.’s titanium total artificial heart (TAH) sent real hearts aflutter at the Huntington, Calif.-based company’s ...

Credit: Getty Images A discussion of the history and future of artificial heart technology with Dr Francisco Arabia and Dr Jack Renfrew’s experience with an artificial heart transplant. In May 2025, ...